Target intelligence / Profile preview

Sialic acid-binding Ig-like lectin F receptor (Siglec-F) (Siglec-F)

Target
Siglec-F
Molecular classification
Receptor, Immunoglobulin superfamily/lecrin (I-type lectin), Type 1 transmembrane protein
01

Overview

Sialic acid-binding Ig-like lectin F receptor (Siglec-F) is a mouse-specific, single-pass type I transmembrane protein belonging to the immunoglobulin superfamily and classified as a CD33-related Siglec (CD33rSiglec)[3]. It consists of four extracellular immunoglobulin-like domains, a transmembrane domain, and a cytoplasmic tail containing two immunoreceptor tyrosine-based inhibitory motifs (ITIMs)[3]. Siglec-F is primarily expressed on mature eosinophils and alveolar macrophages[3][5]. It preferentially binds α2,3-linked sialic acid, with a high affinity for 6′sulfo-sialyl-Lewis X[3][5]. Siglec-F functions as an inhibitory receptor: engagement by its natural ligands or by antibodies induces apoptosis in eosinophils, suggesting a role in the negative regulation of eosinophilic inflammation[3][5]. Siglec-F is not a direct ortholog of any human protein; however, its expression pattern and function closely resemble those of human Siglec-8, making it a valuable model for studying eosinophil biology and allergic inflammation[5]. Mouse Siglec-F has been implicated in in vivo negative feedback regulation of eosinophilic responses in murine models of asthma and allergic inflammation, but clinical relevance in humans is limited by the absence of a true ortholog[5]. The receptor’s targeting in mice is primarily experimental, with no approved drugs for clinical use. Safety concerns relate to the risk of unintended immunosuppression, and biomarker utility is currently confined to research settings.

Other names
CD170Siglec5Siglecf
02

Mechanism of action

Antibody-mediated receptor engagement leading to apoptosis; Immunosuppressive signaling through ITIM motifs

03

Biological functions

Apoptosis (induction in eosinophils)Negative regulation of immune responsesCell signaling (ITIM-mediated signal transduction)Immune cell recruitment and activation
04

Disease associations

Inflammation (allergic diseases, asthma, eosinophilic disorders)Other (murine model for eosinophil-associated pathologies)
05

Safety considerations

Potential for abnormal immune suppression if broadly targetedSpecificity for murine models (no direct human ortholog, but Siglec-8 is a functional paralog)
06

Interacting drugs

Targeted antibodies (research use, e.g., anti-Siglec-F monoclonal antibodies)
07

Biomarkers

Eosinophil count in blood and tissuesSiglec-F expression on eosinophils and alveolar macrophages

Beyond the preview

Go deeper on Sialic acid-binding Ig-like lectin F receptor (Siglec-F) (Siglec-F).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sialic acid-binding Ig-like lectin F receptor (Siglec-F) (Siglec-F).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call